Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
03 mars 2020 07h30 HE
|
Kura Oncology, Inc.
– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients – – Company plans to initiate a registration-directed trial of tipifarnib...